Correction to: Viloxazine: Pediatric First Approval
(Source: Pediatric Drugs)
Source: Pediatric Drugs - October 20, 2023 Category: Pediatrics Source Type: research
Topical Management of Pediatric Psoriasis: A Review of New Developments and Existing Therapies
AbstractPsoriasis is a chronic immune-mediated disorder that commonly affects adults and children. In recent years, pediatric psoriasis has increased in prevalence and the disease is often associated with various comorbidities and psychological distress. The conventional topical treatments for psoriasis, such as corticosteroids, calcineurin inhibitors, vitamin D analogs, anthralin, and coal tar, are often limited by their side effects, tolerability, and/or efficacy, particularly for use in children and on sensitive and intertriginous areas. Recently, the US Food and Drug Administration approved two new topical non-steroida...
Source: Pediatric Drugs - October 17, 2023 Category: Pediatrics Source Type: research
Pediatric Drugs, Accelerated Approval, and Prospects for Reform
(Source: Pediatric Drugs)
Source: Pediatric Drugs - October 14, 2023 Category: Pediatrics Source Type: research
Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants
This article summarizes the milestones in the development of RSVpreF leading to the approval for use in pregnant individuals to prevent LRTD in infants. (Source: Pediatric Drugs)
Source: Pediatric Drugs - October 13, 2023 Category: Pediatrics Source Type: research
Diagnosis and Management of Non-Infectious Uveitis in Pediatric Patients
AbstractUveitis in children accounts for 5 –10% of all cases. The causes vary considerably. Classically, uveitis is distinguished according to its infectious or inflammatory origin and whether it is part of a systemic disease or represents an isolated ocular disease. It is important to highlight the specificity of certain etiologies among children such as juvenile idiopathic arthritis. The development of visual function can potentially be hindered by amblyopia (children aged< 7 years), in addition to the usual complications (synechiae, macular edema) seen in adult patients. Moreover, the presentation of uveitis in ...
Source: Pediatric Drugs - October 4, 2023 Category: Pediatrics Source Type: research
Diagnosis and Management of the Systemic Juvenile Idiopathic Arthritis Patient with Emerging Lung Disease
AbstractChronic lung disease in children with systemic juvenile idiopathic arthritis (SJIA-LD) is an emerging and potentially life-threatening disease complication. Despite recent descriptions of its clinical spectrum, preliminary immunologic characterization, and proposed hypotheses regaarding etiology, optimal approaches to diagnosis and management remain unclear. Here, we review the current clinical understanding of SJIA-LD, including the potential role of biologic therapy in disease pathogenesis, as well as the possibility of drug reactions with eosinophilia and systemic symptoms (DRESS). We discuss approaches to evalu...
Source: Pediatric Drugs - October 3, 2023 Category: Pediatrics Source Type: research
Hidradenitis Suppurativa in Children and Adolescents: An Update on Pharmacologic Treatment Options
AbstractHidradenitis suppurativa (HS) is a chronic, recurrent, inflammatory skin condition that manifests as painful, deep-seated, inflamed nodules and abscesses in the axillary, groin, perianal, perineal, and inframammary regions. The associated pain, malodour, and disfigurement contribute to its profound negative impact on psychosocial spheres and overall quality of life in affected individuals. Although the symptoms of HS classically begin in the second or third decade of life, HS affects children and adolescents as well. Despite this, there are limited pediatric data on treatment, which are largely based on expert opin...
Source: Pediatric Drugs - October 2, 2023 Category: Pediatrics Source Type: research
Scope of JAK Inhibitors in Children: Recent Evidence and Way Forward
AbstractOver the last decade, there has been an increase in the use of targeted therapy using small molecules such as Janus kinase (JAK) inhibitors. Since the introduction of ruxolitinib, the first non-selective JAK inhibitor approved for use in myelofibrosis, many other JAK inhibitors have been tried in a wide spectrum of immune-mediated disorders. Although various trials have shown the promising efficacy of JAK inhibitors in immune-mediated inflammatory disorders (IMIDs), there is a growing concern over the major cardiovascular events and malignancies associated with the use of these molecules in older adults, particular...
Source: Pediatric Drugs - September 29, 2023 Category: Pediatrics Source Type: research
Low-Dose Remifentanil in Preterm Cesarean Section with General Anesthesia: A Randomized Controlled Trial
ConclusionsThe use of a low dose of remifentanil before cord clamping for a Cesarean section appears to be safe both for the mother and the preterm newborn, but it does not improve maternal or neonatal outcomes.Clinical Trial RegistrationClinicalTrials.gov: NCT02029898. (Source: Pediatric Drugs)
Source: Pediatric Drugs - September 15, 2023 Category: Pediatrics Source Type: research
Azacitidine (Vidaza ®) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015)
ConclusionsAzacitidine 75 mg/m2 prior to a second hematopoietic stem cell transplantation is safe in children with relapsed MDS/JMML. Although the long-term advantage remains to be assessed, this study suggests that azacitidine is an efficacious option for relapsed JMML.Clinical Trial RegistrationEudraCT 2010-022235-10. (Source: Pediatric Drugs)
Source: Pediatric Drugs - September 11, 2023 Category: Pediatrics Source Type: research
Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab
AbstractSevere asthma in children and adolescents exerts a substantial health, financial, and societal burden. Severe asthma is a heterogeneous condition with multiple clinical phenotypes and underlying inflammatory patterns that might be different in individual patients. Various add-on treatments have been developed to treat severe asthma, including monoclonal antibodies (biologics) targeting inflammatory mediators. Biologics that are currently approved to treat children ( ≥ 6 years of age) or adolescents (≥ 12 years of age) with severe asthma include: anti-immunoglobulin E (omalizumab), anti-interleukin (IL)-5 (mepol...
Source: Pediatric Drugs - September 2, 2023 Category: Pediatrics Source Type: research
Pharmacotherapy for Cancer Treatment-Related Cardiac Dysfunction and Heart Failure in Childhood Cancer Survivors
AbstractThe number of childhood cancer survivors is increasing rapidly. According to American Association for Cancer Research, there are more than 750,000 childhood cancer survivors in the United States and Europe. As the number of childhood cancer survivors increases, so does cancer treatment-related cardiac dysfunction (CTRCD), leading to heart failure (HF). It has been reported that childhood cancer survivors who received anthra cyclines are 15 times more likely to have late cancer treatment-related HF and have a 5-fold higher risk of death from cardiovascular (CV) disease than the general population. CV disease is th...
Source: Pediatric Drugs - August 28, 2023 Category: Pediatrics Source Type: research
The Future of Advanced Therapies for Pediatric Crohn ’s Disease
AbstractPediatric Crohn ’s disease commonly presents with moderate-to-severe intestinal inflammation with a greater risk of complications if remission is not achieved. Anti-tumor necrosis factor therapies have offered the possibility of deep and durable remission; however, many children do not respond or no longer respon d over time. Further, some children do not require broader systemic immunosuppression to achieve remission and are better served by an alternative treatment strategy. Proper utilization of advanced biologic and small-molecule therapies, which have become available for adult patients since anti-tumor necr...
Source: Pediatric Drugs - August 23, 2023 Category: Pediatrics Source Type: research
Impact of Dexmedetomidine Infusion on Opioid and Benzodiazepine Doses in Ventilated Pediatric Patients in the Cardiac Intensive Care Unit
ConclusionWhile in patients ventilated< 5 days opioids initially increased and then quickly decreased in the 72 h following DEX initiation, among patients ventilated ≥ 5 days opioids doubled, then decreased only minimally; benzodiazepines decreased minimally in both groups, although more slowly in the long-ventilation cohort. These findings may inform decision-making on timing of DEX initiation in ventilated patients already being treated with opioid or benzod iazepine infusions. (Source: Pediatric Drugs)
Source: Pediatric Drugs - August 7, 2023 Category: Pediatrics Source Type: research
Fetal, Preterm, and Term Neonate Exposure to Remifentanil: A Systematic Review of Efficacy and Safety
ConclusionsRemifentanil appears to be effective and safe in the short term in preterm and full-term neonates. However, its safety is compromised by the risk of chest wall rigidity. It should be used in appropriate neonatal units and in the presence of physicians able to monitor its side effects. Long-term outcomes have not been evaluated, to our knowledge. (Source: Pediatric Drugs)
Source: Pediatric Drugs - August 4, 2023 Category: Pediatrics Source Type: research
